Scott Reuben

Scott Reuben
Name	Scott Reuben
Birth date	1958
Birth place	United States
Death date	2023
Occupation	Anesthesiologist
Known for	Fabricated clinical research

Scott Reuben was an American anesthesiologist whose published clinical trials on pain management and perioperative analgesia were later found to be largely fabricated, prompting widespread retractions and scrutiny of peer review and evidence-based practice. His case influenced policy changes at journals, hospitals, and regulatory bodies and prompted reassessment of analgesic guidelines that had cited his work.

Early life and education

Reuben completed undergraduate and medical training in the United States, undertaking residency and fellowship positions that prepared him for academic practice. He held appointments at university-affiliated hospitals and maintained affiliations with professional organizations tied to anesthesiology and perioperative medicine. During his early career he engaged with clinical trial networks and collaborated with colleagues at academic centers and pharmaceutical companies.

Career and research

As a faculty anesthesiologist, he published numerous randomized controlled trials and review articles addressing postoperative pain, analgesic regimens, and multimodal pain management. His publications appeared in leading specialty journals and were cited by guideline committees, professional societies, and clinicians shaping perioperative protocols. He reported findings on agents including COX-2 inhibitors, local anesthetics, opioid-sparing strategies, and adjuvant analgesics, influencing practice statements from organizations involved in surgical care, pain management, and anesthesia.

Fabrication scandal and retractions

Investigations by academic institutions, journal editors, and regulatory bodies revealed that many of his reported trials had no underlying patient data or that the data were falsified. Editors of multiple peer-reviewed journals issued expressions of concern and subsequently retracted a series of articles. The scandal prompted editorial reviews, corrections to clinical systematic reviews and meta-analyses, and scrutiny of prior guideline recommendations that had incorporated his findings.

Legal consequences and professional sanctions

Legal and institutional responses included criminal investigation and prosecution related to research fraud and false statements to federal agencies, resulting in charges and sentencing in criminal court. Professional licensing boards and hospital credentialing committees reviewed his clinical privileges, and he faced suspensions and revocations of clinical practice rights. Settlements and restitution obligations were pursued in connection with grants and payments from pharmaceutical companies and research sponsors.

Impact on medical practice and literature

The exposure of fabricated trials led to reassessment of evidence underpinning perioperative analgesic protocols, with guideline panels, systematic reviewers, and evidence-based medicine groups reevaluating recommendations that had relied on his work. Publishers and journals strengthened editorial policies, data verification, and conflict-of-interest disclosures. The case became a cautionary example cited in discussions by medical schools, professional societies, and regulatory agencies concerning research integrity, peer review robustness, and the reproducibility of clinical research.

Personal life and death

He resided in the United States and had professional and personal affiliations with colleagues and institutions in anesthesiology and perioperative care. He died in 2023. United States institutions and professional communities continued to reflect on the ramifications of his misconduct for clinical research and patient care.

Category:American anesthesiologists Category:Medical research misconduct